<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21680">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01884012</url>
  </required_header>
  <id_info>
    <org_study_id>KEK 2012-0538</org_study_id>
    <nct_id>NCT01884012</nct_id>
  </id_info>
  <brief_title>Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized-controlled, cross-over trial the investigators test the effect of
      long-term oxygen therapy (&gt; 16h/day) given for 5 weeks with a wash-out period between phases
      of 2 weeks on exercise performance and quality of life and many physiological parameters in
      patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>6 minute walk test</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>6 minute walk distance according to ATS guidelines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>QoL assessed by the SF-36 questionnaire physical functioning scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily activity</measure>
    <time_frame>5 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>measured by actigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodynamics by echocardiography</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Full echocardiographic assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>short form of the medical outcome questionnaire [SF-36]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial blood gas</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>PaO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>operating hours of oxygen concentrator</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>efficacy of oxygen treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean nocturnal oxygen saturation</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ambulatory Sleep Study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tests of cognitive performance</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>STROOP-Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Minnesota living with heart failure questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous blood</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>NT-proBNP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Supplemental oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplemental oxygen 3 liters/minute given via a nasal cannula for 16 hours a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham room air</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Room air given at a flow rate of 3 liters per minute for 16 hours a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>long term oxygen therapy</intervention_name>
    <arm_group_label>Supplemental oxygen</arm_group_label>
    <arm_group_label>Sham room air</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        - Adult patients with established diagnosis of pulmonary arterial or chronic
        thromboembolic PH (class I and IV according to the latest WHO classification scheme of
        Dana Point 2008) on optimized medical therapy and in stable condition for at least 4
        weeks, who desaturate in the 6 minute walking test by =4% to values &lt;92%.

        Exclusion criteria:

          -  Patients in unstable conditions requiring frequent therapeutic adaption

          -  pregnant women

          -  patients with pulmonary venous hypertension due to left heart diseases

          -  patients with relevant concomitant lung disease and severe daytime hypoxemia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Silvia Ulrich Somaini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Pneumology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Ulrich Somaini, MD</last_name>
    <email>silvia.ulrich@usz.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Pneumology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Ulrich, MD</last_name>
      <phone>++41442554362</phone>
      <email>silvia.ulrich@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 18, 2013</lastchanged_date>
  <firstreceived_date>May 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
